Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1.
Anna D Staniszewska, Domenic Pilger, Sonja J Gill...
https://pubmed.ncbi.nlm.nih.gov/37967136/Actively Recruiting
Led by AstraZeneca · Updated on 2026-10-05
695
Participants Needed
32
Research Sites
N/A
Total Duration
Researchers are evaluating AZD9574, both alone and combined with other anti-cancer drugs, in people with advanced solid tumors that have returned or worsened. This modular phase IIIa study aims to assess the safety, tolerability, how the drug moves and acts in the body, and preliminary effectiveness. The study includes participants with various advanced cancers, including ovarian, breast, pancreatic, prostate, and glioma, among others, with specific genetic mutations related to DNA repair. Participants will receive AZD9574 alone or with other treatments like temozolomide, trastuzumab deruxtecan, or datopotamab deruxtecan, depending on their cancer type and study module. The study has several parts, including dose escalation and expansion phases, with some participants receiving oral AZD9574 and others receiving combinations with intravenous drugs. Some modules include additional imaging studies and biomarker testing to evaluate drug effects. During the study, participants will undergo regular assessments including scans, blood tests, heart monitoring, and evaluations of cancer response and side effects. Researchers will track adverse events, lab changes, and performance status from first dose through about three years post-treatment. The study also monitors how the drug is processed in the body and its effects on tumors over time. Participation length varies depending on study module and response, with ongoing safety follow-up after treatment ends.
CONDITIONS
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
A
AstraZeneca Clinical Study Information Center
A
AstraZeneca Breast Cancer Study Locator Service
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
AstraZeneca
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | AZD9574 (investigational) | Approved PARP inhibitors (current care context) |
|---|---|---|
| What it is | A brain‑penetrant, highly selective PARP1 inhibitor given as monotherapy or combined with agents like temozolomide, T‑DXd, or Dato‑DXd in a dose‑escalation and expansion design. | PARP inhibitors such as olaparib, rucaparib, niraparib and talazoparib are established treatments for HRR‑deficient solid tumors including ovarian, breast, pancreatic and prostate cancers. |
| Role in trial | Investigational agent evaluated through sequential modules of dose escalation and expansion across several tumor types. | Not included in the study arms; serves as external comparator representing current treatment options. |
| Primary purpose | To treat advanced solid tumors with PARP1‑selective intervention and explore safety, tolerability, pharmacokinetics and preliminary efficacy in HRR‑deficient cancers. | Used as approved therapy to target HRR‑deficient cancers via PARP inhibition. |
| Administration | Administered orally as monotherapy or combined with intravenous agents according to module protocols in a first‑in‑human sequential dose‑escalation format. | Approved PARP inhibitors are administered orally, typically as maintenance or therapeutic regimens in HRR‑deficient solid tumors. |
| Evidence status | Preclinical data support BBB penetration, PARP1 selectivity, and activity in CNS‑involved solid tumor models; human safety and efficacy data pending. | Clinical trials have demonstrated effectiveness of PARP inhibitors in prolonging progression‑free survival in HRR‑deficient ovarian, breast, prostate and pancreatic cancers. |
| Known or potential risks | Safety profile not established in humans; potential risks unknown pending early‑phase data. | Standard PARP inhibitors have known hematological toxicities, including anemia, neutropenia and thrombocytopenia. |
| Limitations | Findings limited to early‑stage dose escalation; efficacy, safety and optimal dose yet to be determined. | Response to PARP inhibitors varies across non‑BRCA HRR gene mutations; resistance mechanisms limit durability. |
| Patient impact | Not yet established in patients. | PARP inhibitors have improved progression‑free survival for selected HRR‑deficient cancers. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 to 2 visits depending on assessments
Duration - Up to 12 treatment cycles, varying by module
Participants receive AZD9574 alone or with other anti-cancer drugs depending on their assigned study module and cancer type. Dosing is adjusted in phases to evaluate safety and tolerability.
Regular visits during treatment cycles for drug administration and assessments
Duration - Approximately three years
After treatment ends, participants are monitored for safety and cancer response through regular assessments, including scans and lab tests, for up to about three years.
Periodic visits for ongoing safety and efficacy evaluations
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
9
Have more questions? Get in touch with our team for quick support
Anna D Staniszewska, Domenic Pilger, Sonja J Gill...
https://pubmed.ncbi.nlm.nih.gov/37967136/AstraZeneca
Lead Sponsor